The Preliminary Safety and Efficacy of RRG001 After Vitrectomy in Subjects With Proliferative Diabetic Retinopathy (PDR)

Inclusion Criteria: * Able and willing to provide informed consent * Age \>= 20 years * Diagnosis of diabetes mellitus (type 1 or type 2) * The study eye diagnosed with PDR, in the opinion of the investigator, requires vitrectomy and postoperative anti-VEGF therapy, or that has undergone vitrectomy and still requires postoperative anti-VEGF therapy * Based on the ETDRS chart, the best-corrected visual acuity (BCVA) of the study eye is ≥ hand motion and ≤ 63 letters Exclusion Criteria: * Active infection or inflammation in either eye * Previous gene therapy in either eye * Uncontrolled blood pressure（defined as systolic ≥160mmHg or diastolic ≥ 110mmHg by anti-hypertensive treatment) * HbA1c \>12% for diabetes patients at screening * Previous condition not eligible for study drug * History of major ocular surgery (except for PDR) or severe trauma * Currently enrolled in another clinical trial or planning to enroll during the study * Pregnant or lactating women * Other conditions that, in the opinion of the investigator, would preclude participation in the study Study Eye-Exclusion Criteria： * Ocular disorders that, in the opinion of the investigator, would confound the interpretation of study results or affect the administration * CNV or macular edema secondary to any causes other than diabetic retinopathy * Ocular condition considered by the investigator to contraindicate subretinal injection * Diagnosed primary or secondary glaucoma * History of intraocular corticosteroid treatment